Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis

Prem Kotian, Archith Boloor, Sushanth Sreenivasan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis. Aim: Our article studies the side effect profile and tolerability of parenteral Zoledronic Acid, one of the most potent bisphosphonate used in clinical practice in patients with osteoporosis. Materials and Methods: This study was done in KMC hospitals where 49 patients diagnosed with osteoporosis were included for the study. After obtaining a written informed consent each patient received one infusion of 5 mg Zoledronic Acid as per standard treatment protocol. Patient was monitored for clinical improvement and development of any adverse effects. Conclusion: In our study all subjects reported significant pain relief after infusion of Zoledronic Acid. Zoledronic Acid had very few serious adverse effects that can be prevented through pre-infusion screening, maintaining good hydration and careful patient monitoring. In our population the patients only experienced mild symptoms of pyrexia, arthralgia myalgia and influenza like symptoms which resolved with symptomatic treatment.

Original languageEnglish
Pages (from-to)OC04-OC06
JournalJournal of Clinical and Diagnostic Research
Volume10
Issue number1
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

zoledronic acid
Osteoporosis
Diphosphonates
Patient monitoring
Hydration
Myalgia
Arthralgia
Physiologic Monitoring
Therapeutics
Clinical Protocols
Informed Consent
Screening
Human Influenza
Population
Fever

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Cite this

@article{eddb6840ed6343cfa9aeffd426b409dc,
title = "Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis",
abstract = "Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis. Aim: Our article studies the side effect profile and tolerability of parenteral Zoledronic Acid, one of the most potent bisphosphonate used in clinical practice in patients with osteoporosis. Materials and Methods: This study was done in KMC hospitals where 49 patients diagnosed with osteoporosis were included for the study. After obtaining a written informed consent each patient received one infusion of 5 mg Zoledronic Acid as per standard treatment protocol. Patient was monitored for clinical improvement and development of any adverse effects. Conclusion: In our study all subjects reported significant pain relief after infusion of Zoledronic Acid. Zoledronic Acid had very few serious adverse effects that can be prevented through pre-infusion screening, maintaining good hydration and careful patient monitoring. In our population the patients only experienced mild symptoms of pyrexia, arthralgia myalgia and influenza like symptoms which resolved with symptomatic treatment.",
author = "Prem Kotian and Archith Boloor and Sushanth Sreenivasan",
year = "2016",
month = "1",
day = "1",
doi = "10.7860/JCDR/2016/17061.7021",
language = "English",
volume = "10",
pages = "OC04--OC06",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "1",

}

Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis. / Kotian, Prem; Boloor, Archith; Sreenivasan, Sushanth.

In: Journal of Clinical and Diagnostic Research, Vol. 10, No. 1, 01.01.2016, p. OC04-OC06.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Study of adverse effect profile of parenteral zoledronic acid in female patients with osteoporosis

AU - Kotian, Prem

AU - Boloor, Archith

AU - Sreenivasan, Sushanth

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis. Aim: Our article studies the side effect profile and tolerability of parenteral Zoledronic Acid, one of the most potent bisphosphonate used in clinical practice in patients with osteoporosis. Materials and Methods: This study was done in KMC hospitals where 49 patients diagnosed with osteoporosis were included for the study. After obtaining a written informed consent each patient received one infusion of 5 mg Zoledronic Acid as per standard treatment protocol. Patient was monitored for clinical improvement and development of any adverse effects. Conclusion: In our study all subjects reported significant pain relief after infusion of Zoledronic Acid. Zoledronic Acid had very few serious adverse effects that can be prevented through pre-infusion screening, maintaining good hydration and careful patient monitoring. In our population the patients only experienced mild symptoms of pyrexia, arthralgia myalgia and influenza like symptoms which resolved with symptomatic treatment.

AB - Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early. Bisphosphonates remain the mainstay of osteoporosis treatment as they have multimodal action. Oral bisphosphonate therapy has, significant gastrointestinal side effects leading to noncompliance. Of late parenteral Zoledronic Acid is being used as once or twice yearly infusion for the treatment of osteoporosis. Aim: Our article studies the side effect profile and tolerability of parenteral Zoledronic Acid, one of the most potent bisphosphonate used in clinical practice in patients with osteoporosis. Materials and Methods: This study was done in KMC hospitals where 49 patients diagnosed with osteoporosis were included for the study. After obtaining a written informed consent each patient received one infusion of 5 mg Zoledronic Acid as per standard treatment protocol. Patient was monitored for clinical improvement and development of any adverse effects. Conclusion: In our study all subjects reported significant pain relief after infusion of Zoledronic Acid. Zoledronic Acid had very few serious adverse effects that can be prevented through pre-infusion screening, maintaining good hydration and careful patient monitoring. In our population the patients only experienced mild symptoms of pyrexia, arthralgia myalgia and influenza like symptoms which resolved with symptomatic treatment.

UR - http://www.scopus.com/inward/record.url?scp=84953336147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953336147&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2016/17061.7021

DO - 10.7860/JCDR/2016/17061.7021

M3 - Article

VL - 10

SP - OC04-OC06

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 1

ER -